PharmaResearch Co., Ltd. (KOSDAQ:214450)

South Korea · Delayed Price · Currency is KRW

366,000

-3,000 (-0.81%)

Sep 9, 2026, 3:30 PM KST

Market Cap	3.80T -45.8%
Revenue (ttm)	603.58B +34.2%
Net Income	185.69B +46.2%
EPS	16,711.23 +39.2%
Shares Out	10.39M
PE Ratio	21.90
Forward PE	22.16
Dividend	3,700.00 (0.96%)
Ex-Dividend Date	Dec 29, 2025

Volume	n/a
Open	366,000
Previous Close	369,000
Day's Range	366,000 - 366,000
52-Week Range	255,000 - 696,000
Beta	0.48
Analysts	Strong Buy
Price Target	517,642.86 (+41.43%)
Earnings Date	Nov 11, 2026

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1993

Employees 550

Stock Exchange KOSDAQ

Ticker Symbol 214450

Full Company Profile

Financial Performance

In 2025, PharmaResearch's revenue was 536.29 billion, an increase of 53.18% compared to the previous year's 350.12 billion. Earnings were 165.12 billion, an increase of 79.39%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for 214450 stock is "Strong Buy." The 12-month stock price target is ₩517,643, which is an increase of 41.43% from the latest price.

Price Target

₩517,643

(41.43% upside)

Analyst Consensus: Strong Buy

Stock Forecasts